Immune Modulation, Inc.

Immune Modulation, Inc. develops therapeutics from natural resources for use as anti -cancer, anti-inflammatory and anti-neurodegenerative agents.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Rancho Cucamonga, CA, US
  • Currency USD
  • Founded November 1995
  • Employees 10
  • Incorporation Type C-corp
  • Website imipharma.com

Company Summary

Immune Modulation, Inc. is a Research & Development Bio-tech Company engaged in the development of a promising new pharmaceutical (Hypoestoxide) from natural bioresources to treat and prevent Parkinson's disease for which there is presently no cure. The customers for this novel molecule are the big pharmaceutical companies who rely on in-licensing of certain proprietary pharmaceuticals.

Team

  • Howard B. Cottam, Ph.D.
    Director, Vice President & COO

    Dr. Cottam received his B.S. Degree in Chemistry from ASU in Tempe, Arizona, a Ph.D. in Organic Chemistry from BYU and postdoctoral training in Medicinal Chemistry from BYU Cancer Research Center. Dr. Cottam was most recently Director, Medicinal Chemistry, at The Sam and Rose Stein Inst. at UCSD in San Diego, CA. He previously held an executive position at ICN Pharmaceuticals, Inc. and served as a Consultant to Specialty Laboratories, Inc.

  • Emeka J. Nchekwube, M.D.
    Director, Chief Medical Officer & Secretary

    Dr. Nchekwube received his B.S. degree in Chemistry from Central Michigan University and M.D. from Wayne State University School of Medicine in Detroit, Michigan. He has served as a member of the Board of Directors of several firms including Providence Farms, Inc., Beacon Diagnostics and Quinta Naturaceuticals, Inc. He is an active member of several professional societies including: AMA, CMA and Congress of Neurological Surgeons.

  • Chairman, President & CEO

    Dr. Ojo-Amaize received his B.A. degree in Biology/Biochemistry from Prescott College, Prescott, Arizona, a Ph.D. degree in Cellular Immunology from Uppsala University, Uppsala, Sweden and a Postdoctoral training in Molecular Immunology & Parasitology from New York University, New York, NY. He previously held executive and management positions at Specialty Laboratories, Inc., and ICN Pharmaceuticals, Inc. Prior to ICN, He was a Fellow at UCLA.

Advisors

  • Samir Elamrani
    Unconfirmed

Previous Investors

  • Specialty Laboratories, Inc.
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free